%0 Journal Article %A A. Y. Chong %A N. Brenner %A A. Jimenez-Kaufmann %A A. Cortes %A M. Hill %A T. J. Littlejohns %A J. J. Gilchrist %A B. P. Fairfax %A J. C. Knight %A F. Hodel %A J. Fellay %A G. McVean %A A. Moreno-Estrada %A T. Waterboer %A A. V. S. Hill %A A. J. Mentzer %T A frequent ancestral NFKB1 variant predicts risk of infection or allergy %D 2022 %R 10.1101/2022.11.24.22282707 %J medRxiv %P 2022.11.24.22282707 %X Infectious agents contribute significantly to the global burden of diseases, through both acute infection and their chronic sequelae. We leveraged the UK Biobank to identify genetic loci that influence humoral immune response to multiple infections. From 45 genome-wide association studies in 9,611 participants from UK Biobank, we identified NFKB1 as a locus associated with quantitative antibody responses to multiple pathogens including those from the herpes, retro- and polyoma-virus families. An insertion-deletion variant thought to affect NFKB1 expression (rs28362491), was mapped as the likely causal variant. This variant has persisted throughout hominid evolution and could play a key role in regulation of the immune response. Using 121 infection and inflammation related traits in 487,297 UK Biobank participants, we show that the deletion allele was associated with an increased risk of infection from diverse pathogens but had a protective effect against allergic disease. We propose that altered expression of NFKB1, as a result of the deletion, modulates haematopoietic pathways, and likely impacts cell survival, antibody production, and inflammation. Taken together, we show that disruptions to the tightly regulated immune processes may tip the balance between exacerbated immune responses and allergy, or increased risk of infection and impaired resolution of inflammation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAJM was supported by a Wellcome Trust Fellowship with reference 106289/Z/14/Z and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). AYC was supported by the Research Councils UK Newton Fund Award with reference MR/N028937/1. AJ-K and AM-E were supported by The Mexican Biobank Project (CONACYT-Newton Fund grant number FONCICYT/50/2016). JJG is funded by a National Institute for Health Research (NIHR) Clinical Lectureship. JF was supported by the Swiss National Science Foundation, grant #175603. The research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with additional support from the NIHR Oxford BRC. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank has obtained ethics approval from the North West Multi-centre Research Ethics Committee (approval number: 11/NW/0382) and had obtained informed consent from all participants. The institutional Ethics Committee of the University of Lausanne, which afterwards became the Ethics Commission of Canton Vaud (www.cer-vd.ch) approved the baseline CoLaus study (reference 16/03, decisions of 13th January and 10th February 2003), and written consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics are available to download from Zenodo. https://doi.org/10.5281/zenodo.7347714 https://doi.org/10.5281/zenodo.7347792 %U https://www.medrxiv.org/content/medrxiv/early/2022/11/24/2022.11.24.22282707.full.pdf